Obligatory role of cardiac nerves and alpha1-adrenergic receptors for the second window of ischemic preconditioning in conscious pigs.
We tested the hypothesis that cardiac nerves may mediate ischemic preconditioning. Pigs were chronically instrumented to measure aortic, left atrial and left ventricular pressures, and regional myocardial function (wall thickening). Hemodynamic variables, area at risk, and tissue blood flows (radioactive microspheres) were similar among groups. Myocardial infarct size following 60 minutes coronary artery occlusion and 4 days reperfusion, expressed as a fraction of the area at risk, was 42+/-4.0%, in innervated pigs and similar in pigs with regional cardiac denervation (CD, 41+/-2.5%). Infarct size in innervated pigs during the first window of preconditioning (first window) was markedly reduced (6+/-1.8%, P<0.01), as it was in the second window of preconditioning (second window) (16+/-3.3%, P<0.01). Although infarct size was still reduced in pigs with CD and first window preconditioning (9+/-1.8%, P<0.01), the protective effects of second window were abrogated in pigs with CD resulting in an infarct size of 38+/-5.6%. In another group of innervated pigs during pharmacological alpha(1)-adrenergic receptor (AR) blockade, infarct size was also not reduced during the second window (48+/-3.2%). Additionally, Western blot analysis of inducible nitric oxide synthase and cyclooxygenase-2 proteins demonstrated significant (P<0.05) upregulation following the second window in innervated pigs, but not in pigs with CD or alpha(1)-AR blockade. Thus, the mechanism of protection during the second window, but not the first window, appears to be dependent on cardiac nerves and alpha(1)-AR stimulation.
Kudej
Raymond K
RK
Cardiovascular Research Institute, Department of Cell Biology and Molecular Medicine, UMDNJ-New Jersey Medical School, Newark 07103, USA.
Shen
You-Tang
YT
Peppas
Athanasios P
AP
Huang
Cheng-Hsiung
CH
Chen
Wei
W
Yan
Lin
L
Vatner
Dorothy E
DE
Vatner
Stephen F
SF
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D015153:Blotting, Western; D002316:Cardiotonic Agents / Q000378:metabolism*; D051546:Cyclooxygenase 2 / Q000378:metabolism; D003714:Denervation; D006321:Heart / Q000294:innervation*; D066298:In Vitro Techniques; D019157:Ischemic Preconditioning, Myocardial / Q000145:classification; D009203:Myocardial Infarction / Q000473:pathology; D015428:Myocardial Reperfusion Injury / Q000378:metabolism / Q000503:physiopathology*; D009206:Myocardium / Q000201:enzymology; D009424:Nervous System Physiological Phenomena; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D018340:Receptors, Adrenergic, alpha-1 / Q000378:metabolism; D013552:Swine
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D002316:Cardiotonic Agents; D018340:Receptors, Adrenergic, alpha-1; D052247:Nitric Oxide Synthase Type II; D051546:Cyclooxygenase 2